Vaccines that bind to body’s own albumin move technology closer to eventual use in humans
Cancer fighting nanovaccines have shown significant promise, but clinical application has been hampered by complications in large-scale manufacturing, quality control, and safety. Biomedical engineers at the National Institute of Biomedical Imaging and Bioengineering (NIBIB) developed a new technology that enables nanovaccines to bind to the albumin protein naturally present in the body. The albumin protein then delivers these nanocomplexes to the lymph nodes, resulting in potent immune activation against multiple tumor types in mouse cancer models. The use of natural albumin as a universal vaccine shuttle is a significant step towards the application of cancer nanovaccine immunotherapy in humans.
So, what’s new?
How is it formulated?
Several nanovaccines were engineered, each with a different antigen—the component that stimulates the immune cells to attack a specific tumor type. To each antigen, the engineers also added a small dye molecule called Evans blue (EB), that binds to the albumin in the body and has been used for nearly a century in the clinic to study albumin binding proteins. The vaccine-EB complex was named AlbiVax (albumin-binding vaccine) because it immediately binds to albumin. The nanovaccine also included a small segment of DNA bound to the EB; the DNA is a “danger signal” to the immune system and so helps make the immune response more robust.
Thus, the complete formulation consists of an antigen and a DNA segment, both bound to EB. Upon injection, both components bind to albumin, which is why the vaccine is considered to be self-assembling. The albumin carrying the antigen and the DNA then delivers both to the lymph nodes where the antigen activates immune cells that specifically target the tumor, and the DNA enhances that activation, optimizing the immune attack.
Anti-tumor effects of the AlbiVax nanovaccine
At day 70 a large dose of the tumor cells was injected into seven immunized mice as a challenge. Five of the seven mice survived for more than four months. The five surviving mice were injected again with another large dose of the tumor cells, and four of the five mice survived for more than six months. Blood tests showed that four months after the last immunization, the mice still had circulating immune cells that were specifically killing the thymus tumor cells.
An AlbiVax nanocomplex vaccine was also engineered against a human colon cancer cell line. The human colon cancer cells are injected into the mouse where they establish tumors in various organs. Most tumors lodge in the lung, so the system is a good model of aggressive colon cancer cells that have metastasized to the lung. The mice were given the vaccine six days after the lung tumors were established. In this experiment the mice were also treated with an antibody called anti-PD-1, to counter the effects of the protein PD-1 that appears on the surface of some tumors and acts to slow down the immune attack. In this case, the combination of the nanovaccine and anti-PD-1 resulted in the complete regression of lung tumors in six of the 10 mice for four months.
The team is particularly optimistic about the long-lasting immunity that they were able to induce with the AlbiVax system, as evidenced by continued robust anti-tumor activity for up to six months. This was the longest time point tested in these experiments and represents a significant part of the lifespan of a mouse, which is about two years.
Zhu concludes, “albumin is an interesting protein and it has been studied for over 40 years for drug delivery using different technologies. Compared with other albumin-binding technologies, our proprietary technology has been developed using clinically safe EB, making it very promising for eventual clinical translation. By simply synthesizing albumin-binding vaccines, our technology can be applied to virtually any molecular vaccine or molecular therapeutics.”
The Chief of the NIBIB Laboratory of Molecular Imaging and Nanomedicine is Xiaoyuan Chen, Ph.D., who is the senior author of the publication. Additional laboratories at NIBIB in Bethesda, MD that contributed to the work include the Advanced Imaging and Microscopy Resource, the Laboratory of Cellular Imaging and Macromolecular Biophysics, and the Section on High Resolution Optical Imaging. Additional NIH collaborators included the Laboratory of Molecular Immunology at the National Institute of Allergy and Infectious Diseases, the Cancer and Inflammation Program, National Cancer Institute, Frederick, MD, and the Advanced Imaging and Microscopy resource, NIH, Bethesda. Additional collaborating laboratories included the Molecular Imaging Center, Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, the School of Engineering, China Pharmaceutical University, Nanjing, China, the State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Center for Molecular Imaging and Translational Medicine, and the School of Public Health, Xiamen University, Xiamen, China.
1. Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy. Zhu G, Lynn GM, Jacobson O, Chen K, Liu Y, Zhang H, Ma Y, Zhang F, Tian R, Ni Q, Cheng S, Wang Z, Lu N, Yung BC, Wang Z, Lang L, Fu X, Jin A, Weiss ID, Vishwasrao H, Niu G, Shroff H, Klinman DM, Seder RA, Chen X. Nat Commun. 2017 Dec 5. (creativecommons.org/licenses)